by Scott Ford | Jan 22, 2026 | Cancer, Cancer Biopsy, Cancer Testing, Cryopreserve Tissue, Cryopreserved Tissue
FFPE vs Cryopreservation – A Biopsy Guide for Cancer Patients Key Takeaways Standard Care: Most hospitals use FFPE (Formalin-Fixed Paraffin-Embedded) as the default preservation method. Preservation Limits: The chemicals in FFPE can damage DNA and RNA,...
by Scott Ford | Jan 16, 2026 | Cancer, Cancer Biopsy, Cancer Testing, Cancer Treatments, Clinical Trials, Cryopreserve Tissue
The Biopsy Trap: When Your Sample Gets Used Up Too Fast Quick Takeaways Tissue exhaustion occurs when a biopsy sample is too small to complete all necessary tests. Standard hospital processing (FFPE) often uses up significant portions of the sample for initial...
by Scott Ford | Dec 29, 2025 | Cancer, Cancer Biopsy, Cancer Testing, Cancer Treatments, Clinical Trials, Cryopreservation, Cryopreserved Tissue
AI-Powered Cancer Care Why Forward-Thinking Patients Are Demanding Precision Testing Before Treatment The statistics are sobering: approximately 50% of first-time cancer treatments fail. After months of grueling chemotherapy, radiation, or targeted therapy, half of...
by Scott Ford | Dec 15, 2025 | Cancer, Cancer Biopsy, Cancer Testing, Cancer Treatments, Clinical Trials, Cryopreservation, Cryopreserve Tissue
Three Advanced Cancer Tests Most Patients Never Hear About—and Why Tissue Preservation Comes First In the United States, cancer is not a rare event—it’s a common life chapter for far too many families. Depending on how you count and which population statistics you...
by Scott Ford | Dec 11, 2025 | Cancer, Cancer Biopsy, Cancer Testing, Cancer Treatments, Clinical Trials, Cryopreservation
Cancer care is in the middle of a quiet revolution—and the smartest money in healthcare has noticed. In the last few weeks alone: Abbott announced a ~$21–23 billion acquisition of Exact Sciences, the company behind Cologuard and major precision-oncology assays like...
Recent Comments